Researchers surveyed clinicians from 63 countries and found that adalimumab and infliximab biosimilars, primarily chosen for their lower cost, are widely available and have improved access to biologic treatment in inflammatory bowel disease (IBD).
Researchers surveyed clinicians from 63 countries to better understand whether biosimilars have improved access to biologic treatment in inflammatory bowel disease (IBD). They found that adalimumab and infliximab biosimilars are available in most cases, and the lower cost of biosimilars was the main driver of treatment choice.
Image credit: Syda Productions - stock.adobe.com
Crohn disease (CD) and ulcerative colitis (UC), collectively referred to as IBD, are inflammatory diseases of the digestive tract. Biologic therapies have “revolutionized the management of IBD patients by reducing the rate of negative outcomes,” the authors said. Infliximab and adalimumab, both monoclonal antibodies targeting tumor necrosis factor (TNF)-α, were the earliest biologic therapies indicated for patients with IBD unresponsive to conventional treatment.
The authors aimed to better understand the impact of biosimilar availability on patient care with their international survey that included questions on availability, cost, and recommendations for biosimilars. A total of 233 physicians from 63 countries, most of whom (86%) had more than 10 years of practice, participated in the survey. The most frequently represented countries were Italy (17%), Brazil (6%), Belgium (3%), Egypt (3%), France (3%), and Spain (3%). Most survey respondents were gastroenterologists (88%).
Almost all respondents (95%) reported that biosimilars were available in their clinical practice, 87% had access to both infliximab and adalimumab biosimilars, and at least two-thirds reported that more than 1 biosimilar of adalimumab (77%) or infliximab (67%) was available. Of the 5% who did not have access to biosimilars, most (83%) reported that their center did not purchase them, and smaller numbers reported that there was no difference in cost compared to the reference product (8%) or that they lacked confidence in the effectiveness of biosimilars (8%).
Regarding choosing 1 biosimilar over the other, the main criteria reported by respondents was availability (14%), followed by cost (13%), device characteristics (8%), hospital indications (7%), and insurance recommendations (4%).
The cost of adalimumab and infliximab biosimilars were reported to be approximately 30% less than their reference products. However, only a few physicians reported that savings from the use of biosimilars allowed them to improve patient care (1%) or improve research (1%). Just over half of respondents (52%) reported that the cost of biologics was a limitation for patient access. Forty-two percent of respondents said that the availability of biosimilars did not influence their treatment decisions in CD, and 50% said the same for UC.
The authors concluded the lower cost of infliximab and adalimumab biosimilars compared to originators was the main driver of treatment choice in IBD. They added that future research could address the effects of ustekinumab and vedolizumab biosimilars on patient access.
Reference
D'Amico F, Peyrin-Biroulet L, Danese S. Benefits of biosimilars in the management of patients with inflammatory bowel disease: an international survey. J Clin Med. 2024;13(11):3069. doi:10.3390/jcm13113069
How AI Can Help Address Cost-Related Nonadherence to Biologic, Biosimilar Treatment
March 9th 2025Despite saving billions, biosimilars still account for only a small share of the biologics market—what's standing in the way of broader adoption and how can artificial intelligence (AI) help change that?
Will the FTC Be More PBM-Friendly Under a Second Trump Administration?
February 23rd 2025On this episode of Not So Different, we explore the Federal Trade Commission’s (FTC) second interim report on pharmacy benefit managers (PBMs) with Joe Wisniewski from Turquoise Health, discussing key issues like preferential reimbursement, drug pricing transparency, biosimilars, shifting regulations, and how a second Trump administration could reshape PBM practices.
From Amjevita to Zarxio: A Decade of US Biosimilar Approvals
March 6th 2025Since the FDA’s groundbreaking approval of Zarxio in 2015, the US biosimilars market has surged to 67 approvals across 18 originators—though the journey has been anything but smooth, with adoption facing hurdles along the way.